KNSA vs RCUS vs IMVT vs CRL vs IQV

For growth investors, Kiniksa Pharmaceuticals, Ltd.

(KNSA) is the stronger pick with 60. 1% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Kiniksa Pharmaceuticals, Ltd. (KNSA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus Kiniksa Pharmaceuticals, Ltd. at 78. 1x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 0x.

Over the past 5 years, Kiniksa Pharmaceuticals, Ltd.

(KNSA) delivered a total return of +298. 4%, compared to -46. 6% for Charles River Laboratories International, Inc. (CRL). Over 10 years, the gap is even starker: KNSA returned +201. 0% versus RCUS's +49. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kiniksa Pharmaceuticals, Ltd.

(KNSA) is the lower-risk stock at 0. 20β versus Arcus Biosciences, Inc. 's 1. 84β — meaning RCUS is approximately 818% more volatile than KNSA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Kiniksa Pharmaceuticals, Ltd.

(KNSA) is pulling ahead at 60. 1% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Kiniksa Pharmaceuticals, Ltd. grew EPS 225. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, KNSA leads at 45. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Kiniksa Pharmaceuticals, Ltd.

(KNSA) is the more profitable company, earning 8. 7% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 8. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 0x forward P/E versus 42. 8x for Kiniksa Pharmaceuticals, Ltd. — 28. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IMVT: 57. 2% to $45. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kiniksa Pharmaceuticals, Ltd.

(KNSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 20), +201. 0% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KNSA: +201. 0%, RCUS: +49. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KNSA is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.